#USA #Phoenix #global CDMO #Injectable Drugs #ROIS

ROIS Expands Global Reach with New US Facility

ROIS, a prominent Contract Development and Manufacturing Organization (CDMO) with roots in Spain, is making waves in the pharmaceutical industry by expanding its operations to the United States. On April 1, 2026, ROIS announced its acquisition of a commercial injectable manufacturing and packaging facility located in Phoenix, Arizona. This strategic move not only marks a significant milestone in ROIS's journey but also positions the company as a key player in the competitive landscape of injectable drug manufacturing.

The new facility in Phoenix enhances ROIS's capabilities in producing sterile injectables, which are crucial for treating various conditions including rare diseases, obesity, and cancer. This expansion brings added capacity, flexibility, and speed to ROIS's operations while also integrating new technologies for Antibody-Drug Conjugates (ADCs) and cytotoxic lyophilized (LYO) fill-finish processes. As Kimberlee Steele, the newly appointed Chief Commercial Officer, stated, this acquisition is a pivotal moment for the company.

The Phoenix site was officially launched on April 9, 2026, with local leaders such as Mayor Kate Gallego expressing support for ROIS’s mission. In her State of the City address, she emphasized the importance of specialized injectables in medical care and highlighted ROIS's potential to drive growth in this promising area. The combination of ROIS's advanced manufacturing capabilities and Phoenix's robust university partnerships may create an ecosystem conducive to innovation and health advancements.

ROIS has built a solid reputation as a reliable partner in the development and manufacturing of injectable drugs. The company prides itself on offering end-to-end solutions that cover clinical production through to large-scale commercial supply. Their focus on investing in facilities, equipment, and talent ensures they meet the increasing demand for injectable drugs globally, reinforcing ROIS's commitment to quality and innovation.

As one of the top three sterile CDMO capacities for injectables in the world, ROIS collaborates with over 30 global pharmaceutical clients, ensuring compliant and efficient manufacturing practices. The facility in Phoenix will enhance ROIS’s ability to respond to customer needs and broaden its presence in the lucrative U.S. market, making it a formidable competitor in the industry.

Looking ahead, ROIS aims to leverage its expanded global footprint to further enhance its product offerings and solidify its position as the partner of choice for companies in need of injectable medicines. With regulatory approvals from major authorities, including the FDA, EMA, and others, ROIS is well-equipped to scale its operations while maintaining the high standards expected in the pharmaceutical sector.

For more information and updates on ROIS and its offerings, visit www.roiscdmo.com.

Summary

The establishment of the US facility is not just a business growth strategy for ROIS; it's a commitment to enhancing healthcare through advanced injectable drug capabilities. This expansion illustrates ROIS’s dedication to innovation, quality, and sustainable growth in addressing the healthcare challenges of today.